Skip to main content
. Author manuscript; available in PMC: 2019 Jun 13.
Published in final edited form as: Oral Oncol. 2018 Apr 17;81:45–51. doi: 10.1016/j.oraloncology.2018.04.008

Table 2.

Best overall response.

Nivolumab (n = 240) IC (n = 121)
Best overall response, n (%)
 Complete response 7 (2.9) 1 (0.8)
 Partial response 25 (10.4) 6 (5.0)
 Stable disease 55 (22.9) 43 (35.5)
 Progressive disease 99 (41.3) 42 (34.7)
 Unable to determine 54 (22.5) 29 (24.0)
ORR,% (95% CI) 13.3 (9.3–18.3) 5.8 (2.4–11.6)
Time to response, median (range), mo 2.1 (1.8–7.4) 2.0 (1.9–4.6)
Duration of response, median (range), mo 9.7 (2.8 to 32.8+) 4.0 (1.5 + to 11.3)

CI, confidence interval; IC, investigator’s choice; ORR, objective response rate.